Tag: CS5001
Clinical Trial Application Submitted for CS5001 (ROR1 ADC) in Combination with...
Shanghai (China) base CStone Pharmaceuticals has submitted a Phase 1b clinical trial application in Australia for CS5001, a receptor tyrosine kinase-like orphan receptor 1 (ROR1-) targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for the treatment of Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL).
FDA Approves Investigational New Drug of CS5001, a Potential Best-in-class ROR1-targeting...
The U.S. Food and Drug Administration (FDA) has authorized further development of CS5001, a potential global best-in-class antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like...
